International Journal of Molecular Sciences Review Osteoporosis in Patients with Chronic Kidney Diseases: A Systemic Review 1,2, 3,4, 5,6, Chia-Yu Hsu y , Li-Ru Chen y and Kuo-Hu Chen * 1 Department of Rehabilitation Medicine, Ten-Chan General Hospital, Zhongli, Taoyuan 320, Taiwan;
[email protected] 2 Department of Biomedical Engineering, Chung Yuan Christian University, Taoyuan 320, Taiwan 3 Department of Physical Medicine and Rehabilitation, Mackay Memorial Hospital, Taipei 104, Taiwan;
[email protected] 4 Department of Mechanical Engineering, National Chiao-Tung University, Hsinchu 300, Taiwan 5 Department of Obstetrics and Gynecology, Taipei Tzu-Chi Hospital, The Buddhist Tzu-Chi Medical Foundation, Taipei 231, Taiwan 6 Department of Medicine, School of Medicine, Tzu-Chi University, Hualien 970, Taiwan * Correspondence:
[email protected]; Tel.: +886-2662-89779 These authors contributed equally to this work. y Received: 15 August 2020; Accepted: 16 September 2020; Published: 18 September 2020 Abstract: Chronic kidney disease (CKD) is associated with the development of mineral bone disorder (MBD), osteoporosis, and fragility fractures. Among CKD patients, adynamic bone disease or low bone turnover is the most common type of renal osteodystrophy. The consequences of CKD-MBD include increased fracture risk, greater morbidity, and mortality. Thus, the goal is to prevent the occurrences of fractures by means of alleviating CKD-induced MBD and treating subsequent osteoporosis. Changes in mineral and humoral metabolism as well as bone structure develop early in the course of CKD. CKD-MBD includes abnormalities of calcium, phosphorus, PTH, and/or vitamin D; abnormalities in bone turnover, mineralization, volume, linear growth, or strength; and/or vascular or other soft tissue calcification.